-+ 0.00%
-+ 0.00%
-+ 0.00%

Kangtai Biotech (300601.SZ): Adsorbed Acellular DPT (component) Combined Vaccine (for adults, adolescents and children) ad hoc trial application accepted

Zhitongcaijing·01/08/2026 12:17:14
Listen to the news

Zhitong Finance App News, Kangtai Biotech (300601.SZ) announced that Beijing Minhai Biotechnology Co., Ltd. (“Minhai Biotech”), a wholly-owned subsidiary of the company, received an acceptance notice issued by the State Drug Administration today, agreeing to accept the clinical trial application for the adsorbed acelless (component) combination vaccine (for adults, adolescents and children) developed by Minhai Biotech.